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ABSTRACT
Background: Hypertension and diabetes cause chronic kidney disease (CKD) and diastolic left
ventricular dysfunction (DVD) as forerunners of disability and death. Home blood pressure tele-
monitoring (HTM) and urinary peptidomic profiling (UPP) are technologies enabling prevention.
Methods: UPRIGHT-HTM (Urinary Proteomics Combined with Home Blood Pressure
Telemonitoring for Health Care Reform [NCT04299529]) is an investigator-initiated 5-year clinical
trial with patient-centred design, which will randomise 1148 patients to be recruited in Europe,
sub-Saharan Africa and South America. During the whole study, HTM data will be collected and
freely accessible for patients and caregivers. The UPP, measured at enrolment only, will be com-
municated early during follow-up to 50% of patients and their caregivers (intervention), but
only at trial closure in 50% (control). The hypothesis is that early knowledge of the UPP risk pro-
file will lead to more rigorous risk factor management and result in benefit. Eligible patients,
aged 55–75 years old, are asymptomatic, but have 5 CKD- or DVD-related risk factors, prefer-
ably including hypertension, type-2 diabetes, or both. The primary endpoint is a composite of
new-onset intermediate and hard cardiovascular and renal outcomes. Demonstrating that com-
bining UPP with HTM is feasible in a multicultural context and defining the molecular signatures
of early CKD and DVD are secondary endpoints.
Expected outcomes: The expected outcome is that application of UPP on top of HTM will be
superior to HTM alone in the prevention of CKD and DVD and associated complications and that
UPP allows shifting emphasis from treating to preventing disease, thereby empowering patients.
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The epidemiological transition is a global demo-
graphic change characterised by a longer life expect-
ancy, but the number of years added to the human
life comes at a cost of lower quality of life, i.e. a
greater number of years lived with disability [1]. This
demographic change represents a huge social and eco-
nomic challenge. Health care will have to adjust to
remain sustainable by moving emphasis from the
resource-intensive and costly management of estab-
lished disease to prevention. Given this context,
UPRIGHT-HTM (Urinary Proteomics Combined
with Home Blood Pressure Telemonitoring for Health
Care Reform [NCT04299529]) focuses on chronic
kidney disease (CKD) and diastolic left ventricular
(LV) dysfunction (DVD), as archetypes of chronic
age-related diseases, and as outlined below on two
diagnostic modalities that might contribute to an
improved prevention of CKD and DVD, as forerun-
ners of premature mortality and morbidity.
Blood pressure telemonitoring
Guidelines unanimously recommend out-of-the-office
monitoring as the technique of choice to assess blood
pressure and to diagnose and manage hypertension
[2–4]. According to expert committees, home blood
pressure telemonitoring (HTM) complies with the
state-of-the-art for the long-term follow-up of blood
pressure [5–7]. HTM offers several of the well-recog-
nized advantages of the more complex approach of
ambulatory monitoring. The greater number of read-
ings and the absence of the white-coat effect contrib-
ute to the higher diagnostic accuracy as compared
with office blood pressure readings. If automated
devices are used, the self-recorded blood pressure is
free of observer bias [8]. Two randomised clinical tri-
als, i.e. the Treatment of Hypertension Based on
Home or Office Blood Pressure study (THOP) [9]
and the Home Versus Office Measurement –
Reduction of Unnecessary Treatment (HOMERUS)
trial [10], demonstrated that adjustment of antihyper-
tensive treatment based on the self-measured home
blood pressure avoids needless treatment of white-
coat hypertensive patients with no differences in gen-
eral well-being or target organ damage. More recently,
the HOMED-BP trial (Hypertension Objective
Treatment Based on Measurement by Electrical
Devices of Blood Pressure) proved that the long-term
HTM was well received by hypertensive patients and
that adjusting treatment based on HTM is feas-
ible [11].
Urinary proteomics
Urine is a stable biofluid [12] and contains over
20,000 low-molecular-weight peptides, which can be
analysed on a 10-ml mid-morning urine sample with-
out additional manipulation, such as proteolysis.
Approximately 60% of the total mass of urinary pepti-
des consist of collagen fragments [13]. CKD and
DVD are characterised by a disturbed balance
between collagen synthesis and breakdown, leading to
fibrosis and remodelling of the extracellular matrix
(ECM) [14]. The urinary peptidomic profile (UPP)
does not undergo significant changes when urine is
stored for 6 h at room temperature [15] or for 3 days
at 4C [16]. For studies running over a long time
period, urine can be stored for years at 20 C with-
out UPP alteration [12]. The UPP is well character-
ised and reference standards are available [17]. These
characteristics facilitate the application of UPP in
clinical practice or in clinical trials, as for instance
evidenced by the PRIORITY study [18].
UPP based on capillary electrophoresis coupled to
mass spectrometry (CE-MS) is a powerful technology
to improve the management of chronic diseases
(Figure S1). The CE-MS platform enables the separ-
ation of naturally occurring peptides in a single step,
using a strong electrical field and subsequent detec-
tion by mass spectrometry [19,20]. It is a robust and
operator-independent technology, allowing the high-
resolution detection of several thousands of peptides
(0.8 18 kDa) in a single urine sample. A detailed
description of urine sample preparation, proteome
analysis by CE-MS, data processing and sequencing of
the urinary peptides allowing the identification of par-
ental proteins has been published [19,20] and is sum-
marised in the online only Data Supplement.
Design
UPRIGHT-HTM is an investigator-initiated rando-
mised clinical trial, comparing UPP combined with
HTM (experimental group) with HTM alone (control
group) in risk profiling and as guide to starting or
intensifying management of risk factors to prevent
established disease. This multicentre trial will run in
different countries and continents, is therefore open
for patients of multiple ethnicities, who will be rando-
mised in a 1:1 proportion to the experimental or con-
trol group. UPRIGHT-HTM complies with the
Helsinkyi declaration, General Data Protection
Regulations, and received or is seeking ethical
approval in the countries where the study will be
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running (currently available ethics approvals listed at
https://www.appremed.org/news).
Overview
In short, UPRIGHT-HTM consists of: (i) a run-in
period of variable length (2–5weeks or longer) during
which the eligibility of patients will be checked; (ii)
after stratification for centre and sex a randomised
follow-up period informed by either HTM plus UPP
(experimental group) or UPP alone (control group);
and (iii) for patients leaving randomised follow-up
prematurely a supervised follow-up period during
which the incidence of the primary composite end-
point will be further monitored in consenting patients
(Figure 1). The incidence of endpoints during super-
vised follow-up will contribute to the intention-to-
treat analysis.
Inclusion and exclusion criteria
UPRIGHT-HTM aims to enrol 1148 asymptomatic
patients with high-risk profile, based on their clinical
history, biochemical data, and routine technical
examinations as available in medical records or to be
performed in compliance with current guidelines.
Inclusion criteria
Asymptomatic patients whose age ranges from 55 to 75
(inclusive) can be enrolled, after written informed con-
sent has been obtained. In addition to age, patients
must have at least five additional guideline-defined risk
factors, preferably including hypertension, type-2 dia-
betes mellitus (T2DM), or both (Table 1). Furthermore,
patients must have an email address and internet access
via smartphone (only android will be supported), tablet,
or laptop or desktop computer. Patients must be willing
to engage in HTM for the duration of the study.
Exclusion criteria
Type-1 diabetic patients do not qualify for UPRIGHT-
HTM. Study-specific exclusion criteria include symp-
toms related to renal or LV dysfunction, stage-3B CKD
(i.e. eGFR >45ml/min/1.73 m2), a history of cardiovas-
cular or renal disease within 1 year prior to enrolment,
symptomatic patients, presence of microalbuminuria
Data to be collected on top of home BP
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Figure 1. UPRIGHT-HTM design. eCRF: electronic report forms completed by investigators; EP: absence (-)/incidence (þ) of the
components of the primary endpoint during the run-in/follow-up periods, respectively; IC: written informed consent; pINF: patients
received the UPRIGHT-HTM information sheet and were familiarised with operating the blood pressure monitoring devices; pQ:
patient-administered questionnaires; R: randomisation after stratification for centre and sex; S: initial screening; UPP: urinary prote-
omic profiling (mandatory prior to randomisation – optional at the end of follow-up).
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combined with systolic or diastolic LV dysfunction at
enrolment, and hemodynamic significant valvular heart
disease. Patients who during the run-in period have dif-
ficulties in completing the electronically administered
questionnaires or are not adherent to HTM will not be
randomised. Patients with impracticable echocardio-
graphic window or with atrial fibrillation or flutter or
frequent extrasystoles, will also be excluded, because
these conditions do not allow a reliable assessment of
diastolic LV function. Patients with stage-3A CKD or
asymptomatic DVD at enrolment qualify for entry, but
not those with DVD combined with CKD. Other exclu-
sion criteria are common to all research in humans and
include serious previous or concurrent cardiovascular or
noncardiovascular disease, cancer within 5 years prior to
enrolment, suspected substance abuse, psychiatric illness,
or participation in other studies. However, patients who
experienced a cardiovascular or noncardiovascular event
or a renal complication one year or longer before being
considered for randomisation qualify for entry, if they
fully recovered and are symptomless.
Primary and secondary endpoints
The primary endpoint is a composite of intermediary
and hard cardiovascular-renal endpoints.
Intermediary endpoints
The intermediate endpoints are: new-onset microalbu-
minuria, doubling of serum creatinine, a decrease in
the estimated glomerular filtration rate (eGFR) by 30%
or more or eGFR declining below 45ml/min/1.73 m2
new-onset hypertensive retinopathy (Keith-Wagener
classification [21] or diabetic retinopathy [22], electro-
cardiographic or echocardiographic LV hypertrophy,
cardiac arrhythmias (atrial fibrillation or flutter, fre-
quent ventricular or supraventricular extrasystoles pre-
sent in 20% of cardiac cycles [23], and DVD [24,25].
eGFR will be derived from serum creatinine, using the
Chronic Kidney Disease Epidemiology Collaboration
equation [26]. CKD will be staged according to the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative guideline [27].
In line with the PRIORITY study, the presence of
microalbuminuria should be confirmed in two of
three morning urine samples collected on consecutive
days [18]. In low-resource or primary care settings a
validated dipstick test is acceptable, but a positive dip-
stick test should preferably be confirmed by measur-
ment of the albumin-to-creatinine ratio [28–30]. In
asymptomatic patients, atrial peptides do not provide
reliable diagnostic information on the presence of
silent LV dysfunction [31,32]. Diagnosis of DVD in
the preclinical phase (heart failure stage B) requires
echocardiography. DVD is an abnormally low age-
specific transmitral E/A ratio, indicative of impaired
relaxation, or a mildly-to-moderately elevated left
ventricular filling pressure (E/e’ >8.5) with normal or
decreased age-specific E/A ratio [24,25]. The ejection
fraction should be 50% or higher [24,25]. Higher e’
Table 1. Risk factors.
 type-2 diabetes mellitus
 fasting glycaemia 100mg/dl
 random glycaemia 200mg/dl
 positive oral glucose tolerance test
 HOMA-IR >2.8
 metabolic syndrome
 fasting serum insulin 21 mU
 HbA1c 6.5%
 body mass index 30.0-39.9 kg/m2
 waist circumference 88/102 cm ($/#/)
 current smoking
 total cholesterol >190mg/dl
 high-density lipoprotein cholesterol <46/<40mg/dl ($/#/)
 low-density lipoprotein cholesterol >115mg/dl
 non-HDL cholesterol 130mg/dl
 serum triglycerides >150mg/dl
 aortic pulse wave velocity >10 m/s
 Carotid intima-media thickness 900 m
 “silent” plaques on arterial imaging
 ankle-brachial index <0.9
 office hypertension (140/90mm Hg) (last of three consecutive readings)
 home hypertension (135/85mm Hg)
 24-h ambulatory hypertension (120/80mm Hg
 masked hypertension
 tachycardia (80 beats per minute)
 Sokolow-Lyon index >3.5mV
 Cornell product >2444mVms
 peripheral ECG lead aVl >1.2mV
 left ventricular mass index on echocardiography 95 /115 g/m2 ($/#/)
 family history of premature cardiovascular disease (women before
65 years/men before 55 years)
 serum creatinine 1.2/1.3mg/dl ($/#/)
 eGFR <60ml/min/1.73 m2
 sedentary lifestyle
Risk factors were taken from the 2018 European guideline for the management of hypertension (reference 3). To conduct an oral glucose tolerance test,
WHO recommends a 75-gram orally administered dose of glucose. The fasting plasma glucose should be less than 100mg/dl. To be normal, the 1-hour
and 2-hour plasma glucose levels should be <180mg/dl and <140mg/dl, respectively. HOMA-IR indicates Homeostatic Model Assessment of Insulin
Resistance and is computed as (fasting glucose in mg per decilitre insulin in mU)/405 (PMID 1895955). Metabolic syndrome is the combination of an
increased waist circumference, hypertriglyceridaemia (150mg/dl), decreased high-density lipoprotein cholesterol (<50mg/dl in women and <40mg/dl
in men), office hypertension (blood pressure 140mm Hg systolic or 90mm Hg diastolic), and a (fasting) plasma glucose of 100mg/dl. Masked
hypertension is a normal office blood pressure associated with an increased out-of-the-office blood pressure. Physical inactivity in older individuals is
engaging in less than 150min of moderate-intensity aerobic exercise (3–6 METS) throughout the week (https://www.who.int/dietphysicalactivity/physical-
activity-recommendations-65years.pdf?ua=1). One metabolic equivalent (MET) is defined as the amount of oxygen consumed while sitting at rest and is
equal to 3.5ml O2 per kilogram body weight per minute (PMID 2204507).
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and lower E/e’ on transmitral/tissue Doppler echocar-
diographic imaging, respectively, reflect faster early
diastolic LV relaxation and slower LV filling pressure
(Figure S2).
Hard cardiovascular-renal endpoints
The hard cardiovascular endpoints include cardiovas-
cular mortality (ICD10: I00-I99), and nonfatal myo-
cardial infarction (I21, I22), nonfatal hospitalised
heart failure (I50), nonfatal stroke, not including tran-
sient ischaemic attack (I60-I63), and coronary or per-
ipheral revascularisation. The hard renal outcomes
include macroalbuminuria, the need for renal-replace-
ment therapy, and death due to renal causes (N17,
N18), as defined in recent outcome trials [33].
Sample size
The population [8,34–37] and patient [38–42] studies
and the randomised clinical trials [18,43–49] inform-
ing the sample size calculations are summarised in
the online-only Data Supplement. Sample size calcula-
tions were based on the log-rank test, using SAS soft-
ware, version 9.4. We assumed a study duration of
5 years with patients being recruited over two years,
an annual dropout rate of 2.5%, a 4-year primary
endpoint rate of 20%, and a risk reduction of 30% in
the experimental group. Under these assumptions,
with the a-level set at 0.05 and power at 0.80, 1148
patients would have to be randomised in a 1:1 pro-
portion to the experimental and control group,
respectively (574 per group). Sample sizes based on
alternative assumptions appear in Table S1.
Data collection
UPRIGHT-HTM will run as a patient-centred study,
mainly positioned at the patients’ homes and the
practices of their caregivers by implementation of
modern information technology, under supervision of
the patients’ own primary or specialist care providers.
Data collected by patients
Most data will be collected at the patients’ homes via
web-based applications. For HTM, patients will use
validated [50] OMRON HEM 9210-T (Europe) or
OMRON HEM 9210 T-E (other regions) monitors
(Omron Healthcare Co., Ltd., Kyoto, Japan) fitted
with a cuff that accommodates the range of adults
upper-arm circumferences. Each patient identification
number will be uniquely linked with the serial num-
ber of the HTM device handed over to the patient. If
a patient opts to drop out from the randomised trial
or the supervised follow-up (Figure 1), the carepro-
vider will recuperate the HTM device, check its func-
tionality, and pass it on to another patient. Patients
will be encouraged to measure their blood pressure
after 5min rest in the sitting position preferably
within 1 h after awakening, before breakfast and
before taking any medication, if possible, daily.
Patients who fail to practice HTM at less than weekly
intervals, will receive automatically generated email
reminders but will not be excluded from the inten-
tion-to-treat analysis.
Other data to be collected from patients during the
run-in period, at randomisation and at 6-monthly
intervals during the study (Figure 1) via the web-
based interface are the EQ-5D quality of life question-
naire (www.euroqol.org) and the World Health
Organisation (G. Rose) questionnaires on chest pain,
dyspnoea, claudication, cough and expectorations
[51]. Both questionnaires were translated into all
required local languages. Logistics will be set up in
such a way that patients can collect a 10-ml mid-
morning urine sample for UPP at their homes or at
the practice of their caregiver. These urine samples, to
be collected at baseline, will be stored locally at -20 C
and dispatched in batches to Mosaiques-Diagnostics
GmbH, Hannover, Germany, for UPP analysis.
Investigators will be encouraged to collect an optional
10-ml urine sample from patients, when they leave
the study allowing a longitudinal UPP assessment.
Data collected by caregivers
Caregivers will be responsible for recruiting patients,
obtaining informed written consent, distributing the
HTM devices (one device per patient) and the UPP
test kits, and for collecting depersonalised clinical
data via web-administered electronic case report
forms (eCRFs). Caregivers are free in organising the
follow-up and nonpharmacological and pharmaco-
logical treatment of their patients according to current
national or international guidelines. The online-only
Data Supplement provides suggestions for the man-
agement of hypertension (Figure S3), antidiabetic
therapy (Figure S4) and statin treatment (Table S2).
At screening, caregivers will explain the objectives
of the UPRIGHT-HTM trial to patients verbally and
by handing over the patient information leaflet
together with the HTM monitor. They will complete
an eCRF to document each patient’s anthropometrics,
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office blood pressure and heart rate. This information
is mandatory, because it allows comparing screened
patients not randomised with those randomised. Prior
to randomisation, caregivers will collect informed writ-
ten consent from each patient willing to be enrolled
into the study. The caregivers will locally archive the
consent forms, only available on paper to protect the
patients’ privacy. Prior to randomisation, caregivers
will complete the prerandomisation eCRF showing that
enrolled patients meet all eligibility criteria. Other
information to be collected via the prerandomisation
eCRF includes: (i) anthropometrics; (ii) use of antihy-
pertensive, lipid-lowering, antidiabetic and antiplatelet
medications (only by drug class); (iii) the patient’s
medical history; and (iv) and the presence vs absence
of components of the primary endpoint. During fol-
low-up, the same eCRF will be used at annual follow-
up visit, the end-of-the-randomised follow-up visit,
and the end-of-trial close-out visit. Thus, the contents
of all follow-up eCRFs are similar to that used prior to
randomisation. These eCRFS allow reporting the inci-
dence of the components of the primary endpoint, and
if applicable, the reason why a patient wishes to dis-
continue randomised follow-up, or the justification
why a caregiver withdrew a patient from randomised
or supervised follow-up (Figure 1).
On clinical indication while observing guidelines,
probably at baseline and annual intervals for most
patients, caregivers will collect urine samples required for
the diagnosis of incident microalbuminuria and refer
patients for echocardiography (Table S3) at baseline and
at least once during follow-up. Routine biochemical data
collected within 6 to 9months of the due date of the
eCRF qualify, so that in most cases no blood sampling
for the specific purpose of the study is necessary.
Database management and statistical analysis
For data management and statistical analysis, SAS
software, version 9.4, maintenance level 5 (SAS
Institute, Cary, NC, USA) will be used. The HTM
readings, the electronic questionnaire data collected
directly from patients and the eCRFs completed by
caregivers will reach the study coordinating team via
the WiPam platform (www.wipam.net) as CSV
(coma-separated values) or XML (extensible mark-up
language) files. The UPP data will be emailed to study
team as Excel (XLS or XLSX) email attachments.
After quality control, the CSF, XML, XLS and XLSX
files will be directly imported into a SAS database,
using the SAS PC File Server, version 9.4.
Intention-to-treat and per-protocol analysis
The main analysis will be implemented using the
intention-to-treat dataset. This analysis will address
the intermediate and hard events making up the pri-
mary composite endpoint, which occurred during
randomised and supervised follow-up (Figure 1). This
dataset will include all randomised patients, who were
free of the endpoints of interest at enrolment and
who had at least one endpoint assessed after random-
isation, i.e. during randomised or supervised follow-
up. The per-protocol dataset is a subset of the inten-
tion-to-treat dataset excluding patients randomised,
but not complying with all inclusion and exclusion
criteria, patients deviating from the study protocol to
such extent that they might introduce bias in the ana-
lysis, and excluding the data that accrued during
supervised follow-up (Figure 1).
Stratification and randomisation
Eligible patients will be stratified by centre and sex
and subsequently randomised in a 1:1 proportion
within each stratum to the experimental group (HTM
plus UPP) and control group (HTM alone), using a
random function and permuted blocks. Stratification
and randomisation will be automated via the
WiPam platform.
Masking
Caregivers will know the group to which their
patients were randomly assigned. In the two groups,
both patients and caregivers will have full access to
the HTM data. In both treatment groups, patients
and caregivers will be informed about the UPP risk
profile. However, in the experimental group, patients
will be informed about their UPP risk profile shortly
after randomisation and in the control group, only
when they leave randomised or supervised follow-up
or at the completion of the trial. As implemented in
other randomised controlled trials [52,53], the central
study coordinating team will run interim analyses as
part of the quality control programme, excluding any
component of the primary endpoint, and have these
analyses published in peer-reviewed journals to report
on the progress of the trial. However, the study coor-
dinating team will remain blinded to the primary
endpoint and all of its components until completion
of the trial and until the statistical analysis plan has
been written and all datasets have been cleaned and
frozen for the final analysis.
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For endpoint validation, as implemented in other
investigator-initiated trials [54], each centre will
appoint two junior residents and one senior super-
visor, who will remain blinded to randomisation.
Using a special eCRF, at annul intervals, the study
coordinating team will request validation of potential
endpoints, as reported via the follow-up eCRFs.
Statistical analysis
The primary and secondary endpoints measured on a
continuous scale will be analysed using mixed models.
Between-group comparisons will be executed with
adjustment for baseline. The fixed effects in the model
include randomisation group and, if there is imbal-
ance between the randomised groups at baseline, con-
founders. To account for the correlation between a
patient’s repeated blood pressure and other measure-
ments, models will also account for patient-level ran-
dom effects. Centre-level random effects will be used
to model the possible correlation of measurements
between patients recruited at the same centre. Binary
endpoints, such as the incidence of endpoints, will be
analysed by means of McNemar’s test and hierarchical
mixed-effects regression models. All statistical tests
will be two-sided.
Molecular analyses
The primary analyses will focus on the urinary
markers CKD273 and HF1, which have been widely
validated and for which diagnostic thresholds have
been established and published in the peer-reviewed
literature [18,32,55,56]. However, in pursuit of the
secondary objective to gain deeper insight in the
molecular pathophysiology of early CKD and DVD,
the urinary peptides with known amino-acid sequence
allowing identification of the parent proteins will be
carried through to further analyses as summarised in
Table S4. Peptides linked to a shared pathophysio-
logical process can then be combined in novel multi-
dimensional classifiers, which after validation can be
proposed for clinical use.
Discussion
UPRIGHT-HTM is an investigator-steered, multi-
centre, randomised trial set up in a multicultural con-
text. The main objective is to assess the value of UPP
administered on top of HTM compared with HTM
alone in risk stratification and as guide to early
intervention.
Patient-centred design
UPRIGHT-HTM is a patient-centred minimally intru-
sive study. Giving patients access to health-related
tests is a double-edged asset, because test results can
cause both anxiety or enhance well feeling [57–60].
However, a literature review revealed that, in general,
web-based access to personal health-related informa-
tion does not increase the patients’ anxiety levels,
even in women with breast cancer given access to
laboratory results and imaging studies [58]. What the
studies revealed is that there is a great need to
enhance the patients’ comprehension of results [58].
HTM is a powerful instrument in educating and
empowering patients [61]. In a randomised clinical
trial, involving 450 patients recruited at 59 primary
care practices and followed up for 12months, self-
monitoring and self-titration of antihypertensive
drugs lowered systolic blood pressure 8.8mm Hg
more than usual care based on office blood pressure
measurement [62]. Moreover, self-measurement of
blood pressure increases adherence to antihyperten-
sive drugs [63], allows detecting symptoms that occur
between clinic visits and reduces the number of clinic
visits required for optimising drug treatment [64].
However, self-titration of medication was not consid-
ered as a practicable option in UPRIGHT-HTM,
because of the multi-ethnic and multicultural settings
of the study sites.
Feasibility
Both CKD and DVD are associated with specific UPP
profiles. The multidimensional marker CKD273 pre-
dicts progression of CKD earlier than microalbuminu-
ria does [56]. HF1 is a marker of subclinical DVD
[65]. Both CKD273 [55,56] and HF1 [65] have been
extensively validated in longitudinal patient and
population studies, and CKD273 also in the frame-
work of the PRIORITY study [18]. Pharmacological
treatment, including antihypertensive, lipid-lowering,
antidiabetic and antiplatelet drugs and even immuno-
suppressive drugs in transplant patients [66], have no
noticeable influence on the UPP or its association
with study endpoints. As a working example, Figure 2
proposes how HF1 might be applied in clinical prac-
tice in asymptomatic high-risk individuals [32]. In the
presence of clinical risk factors for DVD, in particular
older age combined with overweight or abdominal
obesity and hypertension (25.1% of the adult popula-
tion [32]), HF1 might be used as a screening tool
[32]. If its value is less than 0.350, managing risk
factors over a 5-year time span is to be recommended.
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In contrast, if HF1 is 0.350 or higher, patients should
not only have their risk factors addressed, but might
be referred for echocardiography to confirm the pres-
ence of DVD [32]. An added benefit of HF1 is that the
marker predicts worsening of renal function [55] and
the 5-year incidence of cardiovascular and cardiac
events [31]. In our studies [32,65], in line with other
publications [67], N-terminal pro-B-type natriuretic
peptide (NT-proBNP) did not add to the prediction of
DVD over and beyond classical risk factors. Moreover,
HF1 in the presence of NT-proBNP fully retained its
prognostic value [32,65].
Two other considerations relate to the feasibility of
URIGHT-HTM. First, drug-adherence is an important
determinant of how well risk factors will be managed
in the intervention and control group. Because of
practicability, the clinical centres will not engage in a
formal and standardised monitoring programme of
drug adherence, other than the information to be col-
lected by the caregivers and to be provided via the
annual eCRFs. However, the home blood pressure
recorded by the patients and the biochemical data,
e.g. blood glucose and eGFR being mandatory fields
in the eCRFs, will generate objective information on
how well risk factors are being controlled. Previous
experience in sub-Saharan Africa confirmed that
adherence to treatment does not grossly differ com-
pared with clinical trials in developed nations [68].
Second, UPRIGHT-HTM will be conducted in afflu-
ent communities, where drug expenses are largely
covered by health insurance. However, cheap generic
drugs are widely available in sub-Saharan Africa.
Diuretics, the cheapest drug class, and generic long-
acting calcium-channel blockers are widely available
in sub-Saharan Africa and are recommended to initi-
ate antihypertensive treatment in Blacks born and liv-
ing in Africa [2–4]. This also applies to metformin,
the first line agent to treat T2DM (Figure S4) [69].
Early intervention
All current guidelines state that risk factor manage-
ment is the foundation for stopping progression of
early towards established disease and in preventing
the target organ damage and the cardiovascular-renal
complications that make up the primary composite
endpoint of UPRIGHT-HTM. Furthermore, guidelines
concur on using angiotensin converting-enzyme
inhibitors (ACEIs) in patients at risk of – or already
having – CKD or heart failure with preserved ejection
fraction, while angiotensin receptor blockers are indi-
cated in ACEI-intolerant patients [5–7]. Addressing
insulin resistance and glycemic control in T2DM are
of primordial importance in patients at risk of DVD
[24,34] and diabetic nephropathy [18]. Spironolactone
did not stop progression of diabetic nephropathy in
PRIORITY [18] or prevent the incidence of cardiovas-
cular complications in patients with diastolic heart
failure enrolled in the Spironolactone for Heart
Failure with Preserved Ejection Fraction (TOPCAT)
trial [70]. However, in the Diastolic Heart Failure
(DHF) trial, a 12-month course with spironolactone
improved diastolic LV function [71]. In patients with
a high risk profile, such as those recruited into
UPRIGHT-HTM, statins will be indicated in most
(Table S2). In patients at risk of CKD, DVD or both,
SGLT2-Is might be particularly indicated, if covered
by health insurance. Indeed, in placebo-controlled tri-
als of very high-risk T2DM patients, SGLT2-Is
improved glycaemic control, lowered office and
ambulatory blood pressure, protected against major
cardiovascular and renal complications, reduced the
incidence of heart failure, and lowered body weight
with no risk of hypoglycaemia [33].
Molecular leads from previous studies
In stage-3 CKD [56,72], there is upregulation of
mucin-1 subunit-a, a protein shed by the renal tubu-
lar epithelium [72]. Mucin-1 is a high-molecular
weight (400 kDa) membrane-tethered glycoprotein
[73], which normal kidneys express in the thick seg-
ment of Henle’s loop and in the distal tubules and
collecting ducts. The main function of mucin-1 is to
shield cell surfaces by maintenance of a luminal epi-
thelial mucobarrier [74]. Further evidence supporting
mucin-1 as a marker of renal dysfunction originated
from genetic studies. A frameshift mutation in the
MUC1 gene, located on chromosome 1 (1q21) [75]
creates a new peptide that accumulates inside the
MUC1 expressing renal tubular cells and causes
Figure 2. Proposal for the clinical application of HF1 over a 5-
year horizon. In a random population sample, 25% of partici-
pants combined three major risk factors for diastolic left ven-
tricular dysfunction. Modified and reproduced with permission
from reference [32].
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autosomal dominant medullary cystic kidney disease
type-1.
With respect to DVD, the urinary proteome
revealed a downregulation of WW domain-binding
protein 11 [65]. The WBP-11 gene encodes a nuclear
protein, which in cell nuclei co-localises with mRNA
splicing factors [76]. In cardiomyocytes, the gene
product, WBP-11, interacts with the 52-amino acid
integral membrane protein phospholamban (PP-1)
and thereby contributes to the regulation of the trans-
membrane Ca2þ flux via the Ca2þ pump (SERCA),
which transports Ca2þ from the cytosol to the sarco-
plasmic reticulum. Phosphorylation of PP-1 by pro-
tein kinase A and dephosphorylation by WBP-11,
respectively, stimulates and inhibits SERCA [77].
Downregulation of WBP-11, as observed in DVD
patients, might enhance SERCA activity and impair
electromechanical coupling in the myocardium [78].
Perspectives
Governments typically invest over 95% of healthcare
budgets in treatment of established disease, even
though prevention generates a lower cost per add-
itional quality-adjusted life-year [79]. If UPRIGHT-
HTM fulfils the expectations underpinning its design,
it will make a strong point for combining HTM with
UPP as model for rigorous risk factor management to
prevent target organ damage and age-related cardio-
vascular-renal complications.
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